HC Wainwright Has Negative Forecast for NRXP Q4 Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Analysts at HC Wainwright reduced their Q4 2027 earnings per share estimates for NRx Pharmaceuticals in a report released on Thursday, May 28th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.36 for the quarter, down from their previous estimate of $0.48. HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($0.12) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ FY2030 earnings at $5.76 EPS.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $19.43 million.

NRXP has been the topic of several other research reports. BTIG Research reaffirmed a “buy” rating and issued a $25.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Friday, May 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Zacks Research raised NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Finally, Ascendiant Capital Markets raised their price objective on NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.25.

NRx Pharmaceuticals Stock Up 3.7%

NASDAQ NRXP opened at $4.44 on Friday. The stock’s 50-day moving average price is $2.73 and its 200-day moving average price is $2.36. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $4.55. The company has a market capitalization of $160.86 million, a P/E ratio of -4.07 and a beta of 2.02.

Institutional Trading of NRx Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ethos Financial Group LLC raised its stake in NRx Pharmaceuticals by 33.6% during the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after purchasing an additional 4,000 shares during the period. One Wealth Management Investment & Advisory Services LLC raised its stake in NRx Pharmaceuticals by 35.3% during the 4th quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock valued at $103,000 after purchasing an additional 9,882 shares during the period. State Street Corp grew its holdings in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after buying an additional 10,700 shares in the last quarter. Sjbenen Advisory LLC purchased a new position in NRx Pharmaceuticals during the 4th quarter valued at approximately $41,000. Finally, Two Sigma Investments LP increased its stake in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares during the last quarter. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.